Study Evaluates Ready-To-Use Botox for Lateral Canthal, Glabellar Lines Treatment

Newly published research in Dermatologic Surgery found liquid nivobotulinumtoxinA was effective and well-tolerated in treating moderate-to-severe lateral canthal lines (LCLs) and glabellar lines (GLs). Jean Carruthers, MD, FRCSC, FRC, co-authored the study, titled “NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.” 

The study enrolled participants with moderate-to-severe LCLs with or without moderate-to-severe GL in 2 double-blind randomized clinical trials. Study 002 participants received nivobotulinumtoxinA 24 units or placebo for LCLs treatment. Study 006 participants received nivobotulinumtoxinA 24 units (LCLs), nivobotulinumtoxinA 44 units (LCLs and GLs), or placebo. Each study allowed up to 2 additional doses. The composite primary end point was the proportion of participants achieving >2-grade improvement on the Facial Wrinkle Scale (FWS) by investigator and participant assessment at maximum smile. The coprimary end point was investigator- and participant-assessed FWS “none or mild” rating.

By Day 30, researchers found significant responder rates were observed for LCLs in Study 002 (30.3% vs 2.6%, p < .001) and for LCLs and LCLs with GL in Study 006 (20.6% and 22.8% vs 0%, p < .001) for the composite end point. “None or mild” investigator/participant assessment of LCL (Study 002: 62.7%/56.5%; Study 006: 56.4%/43.6%) and LCLs with GLs (60.8%/47.3%) were significantly higher compared with placebo (p < .001). Headache was the most reported side effect.